E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

<p>Abstract</p> <p>Background</p> <p>E7080 is an orally active multi-targeted kinase inhibitor whose targets include vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptors (PDGFR). It h...

Full description

Bibliographic Details
Main Authors:	Macleod Kenneth, Patel Hitesh, Mason Susan, Glen Hilary, Brunton Valerie G
Format:	Article
Language:	English
Published:	BMC 2011-07-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/11/309

Similar Items

Pre-clinical investigation and clinical development of E7080, a multi-targeted tyrosine kinase inhibitor : implications for melanoma
by: Glen, Hilary
Published: (2010)

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
by: Osamu Tohyama, et al.
Published: (2014-01-01)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
by: Zhu Z, et al.
Published: (2020-05-01)

Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma
by: Zhao Y, et al.
Published: (2015-08-01)

Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
by: Keisuke Enomoto, et al.
Published: (2021-02-01)

The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer.
by: Diana J Uribe, et al.
Published: (2017-01-01)

The Tyrosine Kinase Pyk2 Promotes Migration and Invasion of Glioma Cells
by: Christopher A. Lipinski, et al.
Published: (2005-05-01)

The receptor tyrosine kinase AXL promotes migration and invasion in colorectal cancer
by: Uribe, Diana J., et al.
Published: (2017)

TYROSINE KINASE INHIBITORS AND PREGNANCY
by: Elisabetta Abruzzese, et al.
Published: (2014-04-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

Mutations in pmrB Confer Cross-Resistance between the LptD Inhibitor POL7080 and Colistin in Pseudomonas aeruginosa
by: Romano, Keith P., et al.
Published: (2020)

Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
by: Yuko Ariza, et al.
Published: (2019-06-01)

LINC02688 and PP7080 as novel biomarkers in early diagnosis of gastric cancer
by: Sadegh Fattahi, et al.
Published: (2021-06-01)

Tyrosine kinase inhibitors in hematological malignancies
by: Kamila Kosior, et al.
Published: (2011-12-01)

Synthesis of new tyrosine kinase inhibitors
by: Sørum, Christopher
Published: (2009)

Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib
by: Åman Pierre, et al.
Published: (2008-01-01)

A spleen tyrosine kinase inhibitor attenuates the proliferation and migration of vascular smooth muscle cells
by: Hyang‑Hee Seo, et al.

Inhibition of Proliferation, Migration, and Matrix Metalloprotease Production in Malignant Mesothelioma Cells by Tyrosine Kinase Inhibitors
by: Zhiwen Liu, et al.
Published: (2004-11-01)

Tyrosine kinases required for <it>Pseudomonas aeruginosa</it> invasion
by: Burrows Lori L, et al.
Published: (2001-02-01)

Tyrosine kinase inhibitor Tofacitinib. Safety issues
by: G. V. Lukina, et al.
Published: (2015-12-01)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
by: Evan Pisick, et al.
Published: (2004-01-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
by: Yi-fan Chen, et al.
Published: (2011-12-01)

Tyrosine kinase inhibitors and hypothyroidism – an intriguing link
by: Davor Kust, et al.
Published: (2016-06-01)

Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease
by: John J. Ryan, MD
Published: (2016-12-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
by: Hor-Yue Tan, et al.
Published: (2018-02-01)

Second-generation inhibitors of Bruton tyrosine kinase
by: Jingjing Wu, et al.
Published: (2016-09-01)

The synthesis of novel inhibitors of protein tyrosine kinases
by: Munawar, Munawar Ali
Published: (1996)

Design and synthesis of protein tyrosine kinase inhibitors
by: Peng, Shao-Zheng, et al.
Published: (1998)

Therapeutic Innovations: Tyrosine Kinase Inhibitors in Cancer
by: Nikolaos Dervisis, et al.
Published: (2016-01-01)

Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
by: Omar Alkharabsheh, et al.
Published: (2021-02-01)

The effect of herbal extracts on Axl receptor tyrosine kinase against the migration and invasion of brain malignant tumor
by: Syue-Rong Chen, et al.
Published: (2009)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
by: Xu H, et al.
Published: (2019-07-01)

Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors
by: Zahra Moradpour, et al.
Published: (2019-01-01)

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
by: Ashraf El-Dabh, et al.
Published: (2019-07-01)

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma
by: Domenico Ribatti
Published: (2010-04-01)

Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
by: D. Samuel Metibemu, et al.
Published: (2019-12-01)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
by: Peng Zeng, et al.
Published: (2020-09-01)

A Review on Newer Tyrosine Kinase Inhibitors and their Uses
by: NITHU M KUMAR, et al.
Published: (2018-08-01)

Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
by: Avadhut D Joshi, et al.
Published: (2012-01-01)

Cannot write session to /tmp/vufind_sessions/sess_1pn1nnjtc50h7h3r2u95tr5750